Some well-known mutations associated with tumorigenesis and progression, such as TP53 [42, 43] and PTEN [44], were enriched in the ARGRS-high group, further supporting the association between ARGRS and worse clinical outcomes in NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.